Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | SVP, Chief Accounting Officer | September 15, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ultragenyx Pharmaceutical Inc.
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,863 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 1,283 · Balance 67,863 F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2021 Filed Apr 19, 2021 21:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027328 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,044 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 17:37 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,000 | $120.69 | $362,070.00 |
DisclosureSEC source: 0001209191-21-018872 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,544 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.68 to $120.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:43 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 4,655 | $0.00 Strike: $142.47 | $0.00 |
DisclosureSEC source: 0001209191-21-017556 · doc4.xml · derivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,655 Underlying: Common Stock · 4,655 shares Expires 2031-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:43 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 732 | $138.17 | $101,140.44 |
DisclosureSEC source: 0001209191-21-017556 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,544 F2 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.16 to $138.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:43 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017556 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,276 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| January 07, 2021 Filed Jan 9, 2021 00:05 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option · Derivative | 4,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002825 · doc4.xml · derivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 4,000 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter. Read SEC document |
| January 07, 2021 Filed Jan 9, 2021 00:05 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,000 | $140.65 | $562,600.00 |
DisclosureSEC source: 0001209191-21-002825 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,716 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.04 to $143.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 214 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2020. Also reflects dispositions from gifts that will be reported in a Form 5 within 45 days after the Issuer's fiscal year end. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| January 07, 2021 Filed Jan 9, 2021 00:05 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 4,000 | $21.00 | $84,000.00 |
DisclosureSEC source: 0001209191-21-002825 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 06, 2020 Filed Feb 4, 2021 01:01 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 934 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007552 · doc5.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,502 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 23:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 146 | $87.98 | $12,845.08 |
DisclosureSEC source: 0001209191-20-055173 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,436 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 21:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-20-042195 · doc4.xml · derivative · entry 4 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 2,000 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 21:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,000 | $91.00 | $182,000.00 |
DisclosureSEC source: 0001209191-20-042195 · doc4.xml · nonDerivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,582 F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 21:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 2,000 | $21.00 | $42,000.00 |
DisclosureSEC source: 0001209191-20-042195 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 21:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 638 | $91.00 | $58,058.00 |
DisclosureSEC source: 0001209191-20-042195 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,582 F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 18:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040944 · doc4.xml · derivative · entry 4 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 1,500 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 18:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,500 | $81.00 | $121,500.00 |
DisclosureSEC source: 0001209191-20-040944 · doc4.xml · nonDerivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,220 F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 18:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 1,500 | $21.00 | $31,500.00 |
DisclosureSEC source: 0001209191-20-040944 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 18:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,111 | $81.00 | $89,991.00 |
DisclosureSEC source: 0001209191-20-040944 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,220 F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 26, 2020 Filed May 27, 2020 19:14 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 260 | $74.93 | $19,481.80 |
DisclosureSEC source: 0001209191-20-032267 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,331 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 25, 2020 Filed May 27, 2020 19:14 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 433 | $73.81 | $31,959.73 |
DisclosureSEC source: 0001209191-20-032267 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,591 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| May 15, 2020 Filed May 19, 2020 23:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030710 · doc4.xml · derivative · entry 4 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 1,500 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter. Read SEC document |
| May 15, 2020 Filed May 19, 2020 23:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,500 | $71.00 | $106,500.00 |
DisclosureSEC source: 0001209191-20-030710 · doc4.xml · nonDerivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,024 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 305 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2020 F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 15, 2020 Filed May 19, 2020 23:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 1,500 | $21.00 | $31,500.00 |
DisclosureSEC source: 0001209191-20-030710 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 19, 2020 23:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 961 | $71.00 | $68,231.00 |
DisclosureSEC source: 0001209191-20-030710 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,719 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 06, 2020 Filed May 9, 2020 00:08 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 138 | $66.26 | $9,143.88 |
DisclosureSEC source: 0001209191-20-028115 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,680 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 19, 2020 Filed Apr 21, 2020 19:33 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 140 | $58.57 | $8,199.80 |
DisclosureSEC source: 0001209191-20-025188 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,818 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:56 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 7,480 | $0.00 Strike: $56.08 | $0.00 |
DisclosureSEC source: 0001209191-20-015757 · doc4.xml · derivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,480 Underlying: Common Stock · 7,480 shares Expires 2030-03-01 F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:56 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 388 | $56.08 | $21,759.04 |
DisclosureSEC source: 0001209191-20-015757 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,058 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:56 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015757 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,446 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 5, 2020 00:44 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 13,280 | $0.00 Strike: $56.08 | $0.00 |
DisclosureSEC source: 0001209191-20-016374 · doc4a.xml · derivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,280 Underlying: Common Stock · 13,280 shares Expires 2030-03-01 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2020 Filed Mar 5, 2020 00:44 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016374 · doc4a.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,958 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| January 14, 2020 Filed Jan 15, 2020 18:08 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,000 | $61.00 | $61,000.00 |
DisclosureSEC source: 0001209191-20-003425 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,946 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 161 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2019 Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 23:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053320 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · SVP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,785 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on October 14, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 25, 2019 Filed May 29, 2019 22:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 433 | $57.18 | $24,758.94 |
DisclosureSEC source: 0001209191-19-033285 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,985 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 21, 2019 Filed May 22, 2019 21:46 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 156 | $59.50 | $9,282.00 |
DisclosureSEC source: 0001209191-19-032140 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,418 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 06, 2019 Filed May 7, 2019 22:52 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-028089 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,574 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on May 6, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 270 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2019. Read SEC document |
| April 19, 2019 Filed Apr 23, 2019 22:38 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 138 | $64.43 | $8,891.34 |
DisclosureSEC source: 0001209191-19-025620 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,504 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 05, 2019 Filed Apr 17, 2019 21:59 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 254 | $65.52 | $16,642.08 |
DisclosureSEC source: 0001209191-19-025117 · doc4a.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,642 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 6,840 | $0.00 Strike: $67.55 | $0.00 |
DisclosureSEC source: 0001209191-19-015752 · doc4.xml · derivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,840 Underlying: Common Stock · 6,840 shares Expires 2029-03-01 F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 246 | $67.55 | $16,617.30 |
DisclosureSEC source: 0001209191-19-015752 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,649 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015752 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,895 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2019 Filed Apr 17, 2019 21:59 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 6,840 | $0.00 Strike: $67.55 | $0.00 |
DisclosureSEC source: 0001209191-19-025117 · doc4a.xml · derivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,840 Underlying: Common Stock · 6,840 shares Expires 2029-03-01 F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2019 Filed Apr 17, 2019 21:59 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025117 · doc4a.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,896 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,448 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-19-000500 · doc4.xml · derivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 2,448 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the option vested one year from January 29, 2014 and then 1/48th monthly thereafter. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 2,448 | $21.00 | $51,408.00 |
DisclosureSEC source: 0001209191-19-000500 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F2 · balance_after: Includes 117 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2018. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 23:55 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,955 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038210 · doc4.xml · derivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,448 Underlying: Common Stock · 2,955 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the option vested one year from January 29, 2014 and then 1/48th monthly thereafter. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 23:55 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 955 | $83.70 | $79,933.50 |
DisclosureSEC source: 0001209191-18-038210 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,940 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 23:55 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 2,955 | $21.00 | $62,055.00 |
DisclosureSEC source: 0001209191-18-038210 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2018 Filed Jun 13, 2018 22:41 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,338 | $76.97 | $102,985.86 |
DisclosureSEC source: 0001209191-18-037560 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,940 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 17:28 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 433 | $67.31 | $29,145.23 |
DisclosureSEC source: 0001209191-18-033718 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,278 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.